Format

Send to

Choose Destination
Eur Urol. 2016 Oct;70(4):611-620. doi: 10.1016/j.eururo.2016.02.056. Epub 2016 Mar 15.

Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.

Author information

1
Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
2
Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
3
Institute of Informatics, University of Warsaw, Warsaw, Poland.
4
Faculty of Biology, University of Warsaw, Warsaw, Poland.
5
Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
6
Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
7
Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: bczernia@mdanderson.org.

Abstract

BACKGROUND:

Progression of conventional urothelial carcinoma of the bladder to a tumor with unique microscopic features referred to as micropapillary carcinoma is coupled with aggressive clinical behavior signified by a high propensity for metastasis to regional lymph nodes and distant organs resulting in shorter survival.

OBJECTIVE:

To analyze the expression profile of micropapillary cancer and define its molecular features relevant to clinical behavior.

DESIGN, SETTING, AND PARTICIPANTS:

We retrospectively identified 43 patients with micropapillary bladder cancers and a reference set of 89 patients with conventional urothelial carcinomas and performed whole-genome expression messenger RNA profiling.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:

The tumors were segregated into distinct groups according to hierarchical clustering analyses. They were also classified according to luminal, p53-like, and basal categories using a previously described algorithm. We applied Ingenuity Pathway Analysis software (Qiagen, Redwood City, CA, USA) and gene set enrichment analysis for pathway analyses. Cox proportional hazards models and Kaplan-Meier methods were used to assess the relationship between survival and molecular subtypes. The expression profile of micropapillary cancer was validated for selected markers by immunohistochemistry on parallel tissue microarrays.

RESULTS AND LIMITATIONS:

We show that the striking features of micropapillary cancer are downregulation of miR-296 and activation of chromatin-remodeling complex RUVBL1. In contrast to conventional urothelial carcinomas that based on their expression can be equally divided into luminal and basal subtypes, micropapillary cancer is almost exclusively luminal, displaying enrichment of active peroxisome proliferator-activated receptor γ and suppression of p63 target genes. As with conventional luminal urothelial carcinomas, a subset of micropapillary cancers exhibit activation of wild-type p53 downstream genes and represent the most aggressive molecular subtype of the disease with the shortest survival. The involvement of miR-296 and RUVBL1 in the development of micropapillary bladder cancer was identified by the analyses of correlative associations of genome expression profiles and requires mechanistic validation.

CONCLUSIONS:

Micropapillary cancer evolves through the luminal pathway and is characterized by the activation of miR-296 and RUVBL1 target genes.

PATIENT SUMMARY:

Our observations have important implications for prognosis and for possible future development of more effective therapies for micropapillary bladder cancer.

KEYWORDS:

Expression profile; Micropapillary bladder cancer; Molecular signature; Prognosis

PMID:
26988609
PMCID:
PMC5804336
DOI:
10.1016/j.eururo.2016.02.056
[Indexed for MEDLINE]
Free PMC Article

Publication type, MeSH terms, Substances, Grant support

Publication type

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center